Skip to main content
Top
Published in: Endocrine Pathology 2/2007

01-05-2007

The Cytoplasmic Expression of MUC1 in Papillary Thyroid Carcinoma of Different Histological Variants and its Correlation with Cyclin D1 Overexpression

Authors: Alexander Abrosimov, Vladimir Saenko, Serik Meirmanov, Masahiro Nakashima, Tatiana Rogounovitch, Olesya Shkurko, Eugeny Lushnikov, Norisato Mitsutake, Hiroyuki Namba, Shunichi Yamashita

Published in: Endocrine Pathology | Issue 2/2007

Login to get access

Abstract

This study addressed the immunohistochemical expression of MUC1 in papillary thyroid carcinoma (PTC) of different histotypes, sizes, and morphological features of aggressiveness, and its correlation with the overexpression of cyclin D1, a target molecule of the Wnt pathway. MUC1 expression was examined in a total of 209 PTCs. Cytoplasmic MUC1 expression was elevated in the tall, columnar cell and oncocytic variants (100%), Warthin-like (78%), and conventional PTCs (61%), and in papillary microcarcinoma (PMC) with the conventional growth pattern (52%). On the contrary, it was low in the follicular variant (27%) of PTC and PMCs with follicular architecture (13%). Cytoplasmic MUC1 accumulation did not associate with any clinicopathological features except peritumoral lymphoid infiltration in PTCs and in PMCs with the conventional growth pattern. MUC1 staining correlated with cyclin D1 overexpression in conventional PTCs and PMCs and PMCs with follicular architecture. The results demonstrate that MUC1 expression varies broadly in different histological variants of PTC, being the lowest in tumors with follicular structure. In general, it does not prove to be a prognosticator of PTC aggressiveness. A high correlation between MUC1 and cyclin D1 implies MUC1 involvement in the Wnt cascade functioning in a large subset of human PTCs and PMCs.
Literature
1.
2.
go back to reference Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins. J Biol Chem 274:31751–4, 1999.PubMedCrossRef Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins. J Biol Chem 274:31751–4, 1999.PubMedCrossRef
3.
go back to reference Alves P, Soares P, Fonseca E, et al. Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens. Endocr Pathol 10:315–24, 1999.PubMed Alves P, Soares P, Fonseca E, et al. Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens. Endocr Pathol 10:315–24, 1999.PubMed
4.
go back to reference Magro G, Schiappacassi M, Perissinotto D, et al. Differential expression of mucins 1–6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. J Pathol 200:357–69, 2003.PubMedCrossRef Magro G, Schiappacassi M, Perissinotto D, et al. Differential expression of mucins 1–6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. J Pathol 200:357–69, 2003.PubMedCrossRef
5.
go back to reference Weiss M, Baruch A, Keydar I, et al. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 66:55–9, 1996.PubMedCrossRef Weiss M, Baruch A, Keydar I, et al. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 66:55–9, 1996.PubMedCrossRef
6.
go back to reference Bieche I, Ruffet E, Zweibaum A, et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7:725–31, 1997.PubMedCrossRef Bieche I, Ruffet E, Zweibaum A, et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7:725–31, 1997.PubMedCrossRef
7.
go back to reference Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780–9, 2004.PubMedCrossRef Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780–9, 2004.PubMedCrossRef
8.
go back to reference Patel KN, Maghami E, Wreesmann VB, et al. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138:994–1001; discussion 1001–2, 2005.PubMedCrossRef Patel KN, Maghami E, Wreesmann VB, et al. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138:994–1001; discussion 1001–2, 2005.PubMedCrossRef
9.
go back to reference Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Bioessays 25:66–71, 2003.PubMedCrossRef Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Bioessays 25:66–71, 2003.PubMedCrossRef
10.
go back to reference Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22:1324–32, 2003.PubMedCrossRef Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22:1324–32, 2003.PubMedCrossRef
11.
go back to reference Wen Y, Caffrey TC, Wheelock MJ, et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278:38029–39, 2003.PubMedCrossRef Wen Y, Caffrey TC, Wheelock MJ, et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278:38029–39, 2003.PubMedCrossRef
12.
go back to reference Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255–65, 1995.PubMedCrossRef Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255–65, 1995.PubMedCrossRef
13.
go back to reference Hatsell S, Rowlands T, Hiremath M, et al. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8:145–58, 2003.PubMedCrossRef Hatsell S, Rowlands T, Hiremath M, et al. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8:145–58, 2003.PubMedCrossRef
14.
go back to reference Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 11:3286–305, 1997.PubMed Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 11:3286–305, 1997.PubMed
15.
16.
go back to reference Ishigaki K, Namba H, Nakashima M, et al. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433–40, 2002.PubMedCrossRef Ishigaki K, Namba H, Nakashima M, et al. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433–40, 2002.PubMedCrossRef
17.
go back to reference Nakashima M, Meirmanov S, Naruke Y, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 202:446–55, 2004.PubMedCrossRef Nakashima M, Meirmanov S, Naruke Y, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 202:446–55, 2004.PubMedCrossRef
18.
go back to reference Lantsov D, Meirmanov S, Nakashima M, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 47:248–56, 2005.PubMedCrossRef Lantsov D, Meirmanov S, Nakashima M, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 47:248–56, 2005.PubMedCrossRef
19.
go back to reference LiVolsi V. Surgical pathology of the thyroid. Philadelphia: Saunders; 1990. LiVolsi V. Surgical pathology of the thyroid. Philadelphia: Saunders; 1990.
20.
go back to reference Rosai J, Carciangiu ML, DeLellis RA. Tumors of the thyroid gland. Washington, D.C.: Armed Forces Institute of Pathology; 1992. Rosai J, Carciangiu ML, DeLellis RA. Tumors of the thyroid gland. Washington, D.C.: Armed Forces Institute of Pathology; 1992.
21.
go back to reference LiVolsi VA, Albores-Saavedra J, Asa SL. Papillary carcinoma. In: DeLellis RA, Lloyd R, Hertz PhU, Eng C, editors. WHO classification of tumors. Pathology and genetics of tumors of endocrine organs. Lyon: IARC Press. p. 57–66, 2004. LiVolsi VA, Albores-Saavedra J, Asa SL. Papillary carcinoma. In: DeLellis RA, Lloyd R, Hertz PhU, Eng C, editors. WHO classification of tumors. Pathology and genetics of tumors of endocrine organs. Lyon: IARC Press. p. 57–66, 2004.
22.
go back to reference Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810–3, 2002.PubMedCrossRef Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810–3, 2002.PubMedCrossRef
23.
go back to reference Hunt JL, LiVolsi VA, Baloch ZW, et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am J Surg Pathol 27:159–66, 2003.PubMedCrossRef Hunt JL, LiVolsi VA, Baloch ZW, et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am J Surg Pathol 27:159–66, 2003.PubMedCrossRef
24.
go back to reference Apel RL, Asa SL, LiVolsi VA. Papillary Hurthle cell carcinoma with lymphocytic stroma. “Warthin-like tumor” of the thyroid. Am J Surg Pathol 19:810–14, 1995.PubMedCrossRef Apel RL, Asa SL, LiVolsi VA. Papillary Hurthle cell carcinoma with lymphocytic stroma. “Warthin-like tumor” of the thyroid. Am J Surg Pathol 19:810–14, 1995.PubMedCrossRef
25.
go back to reference Ozaki O, Ito K, Mimura T, et al. Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–8, 1996.PubMedCrossRef Ozaki O, Ito K, Mimura T, et al. Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–8, 1996.PubMedCrossRef
26.
go back to reference DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–24, 1990.PubMedCrossRef DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–24, 1990.PubMedCrossRef
27.
go back to reference Rahn JJ, Dabbagh L, Pasdar M, et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91:1973–82, 2001.PubMedCrossRef Rahn JJ, Dabbagh L, Pasdar M, et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91:1973–82, 2001.PubMedCrossRef
28.
go back to reference Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646–56, 2005.PubMedCrossRef Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646–56, 2005.PubMedCrossRef
29.
go back to reference Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–20, 2006.PubMedCrossRef Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–20, 2006.PubMedCrossRef
30.
go back to reference Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71–7, 2003.PubMedCrossRef Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71–7, 2003.PubMedCrossRef
31.
go back to reference Shaha AR, Shah JP, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 20:26–30, 1998.PubMedCrossRef Shaha AR, Shah JP, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 20:26–30, 1998.PubMedCrossRef
Metadata
Title
The Cytoplasmic Expression of MUC1 in Papillary Thyroid Carcinoma of Different Histological Variants and its Correlation with Cyclin D1 Overexpression
Authors
Alexander Abrosimov
Vladimir Saenko
Serik Meirmanov
Masahiro Nakashima
Tatiana Rogounovitch
Olesya Shkurko
Eugeny Lushnikov
Norisato Mitsutake
Hiroyuki Namba
Shunichi Yamashita
Publication date
01-05-2007
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 2/2007
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-007-0012-x

Other articles of this Issue 2/2007

Endocrine Pathology 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.